ATE327225T1 - Neue verwendung von benzothiazolderivaten - Google Patents

Neue verwendung von benzothiazolderivaten

Info

Publication number
ATE327225T1
ATE327225T1 AT03788208T AT03788208T ATE327225T1 AT E327225 T1 ATE327225 T1 AT E327225T1 AT 03788208 T AT03788208 T AT 03788208T AT 03788208 T AT03788208 T AT 03788208T AT E327225 T1 ATE327225 T1 AT E327225T1
Authority
AT
Austria
Prior art keywords
sub
new use
benzothiazole derivatives
formula
disclosed
Prior art date
Application number
AT03788208T
Other languages
English (en)
Inventor
Peter Sjoe
Peter Storm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE327225T1 publication Critical patent/ATE327225T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03788208T 2002-08-14 2003-08-13 Neue verwendung von benzothiazolderivaten ATE327225T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202429A SE0202429D0 (sv) 2002-08-14 2002-08-14 Novel Compounds

Publications (1)

Publication Number Publication Date
ATE327225T1 true ATE327225T1 (de) 2006-06-15

Family

ID=20288724

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03788208T ATE327225T1 (de) 2002-08-14 2003-08-13 Neue verwendung von benzothiazolderivaten

Country Status (16)

Country Link
US (1) US20060106015A1 (de)
EP (1) EP1539723B1 (de)
JP (1) JP2006504672A (de)
KR (1) KR20060002728A (de)
CN (1) CN1675189A (de)
AT (1) ATE327225T1 (de)
AU (1) AU2003248587A1 (de)
BR (1) BR0313407A (de)
CA (1) CA2495492A1 (de)
DE (1) DE60305514D1 (de)
IL (1) IL166412A0 (de)
MX (1) MXPA05001585A (de)
NO (1) NO20051263L (de)
SE (1) SE0202429D0 (de)
WO (1) WO2004016600A1 (de)
ZA (1) ZA200501098B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200612925A (en) * 2004-08-26 2006-05-01 Wyeth Corp Prodrug substituted benzoxazoles as estrogenic agents
US7307094B2 (en) 2005-02-17 2007-12-11 Amr Technology, Inc. Benzoxazole carboxamides for treating CINV and IBS-D
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2618370A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
ATE514663T1 (de) * 2007-05-07 2011-07-15 Siemens Ag Keramisches pulver, keramische schicht und schichtsystem mit pyrochlorphase und oxiden
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
JP5628828B2 (ja) 2008-12-19 2014-11-19 サートリス ファーマシューティカルズ, インコーポレイテッド チアゾロピリジンサーチュイン調節化合物
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
EP3060218A4 (de) 2013-10-25 2017-07-19 Pharmacyclics LLC Verfahren zur behandlung und prävention von transplantatabstossung
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
HK1256718A1 (zh) 2015-08-31 2019-10-04 药品循环有限责任公司 用於治疗多发性骨髓瘤的btk抑制剂组合
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
BR112018074990A2 (pt) 2016-06-06 2019-03-12 Beyondspring Pharmaceuticals, Inc. composição, usos e método para reduzir neutropenia
US20190298772A1 (en) 2016-11-03 2019-10-03 Juno Therapeutics, Inc. Combination therapy of a t cell-based therapy and a btk inhibitor
WO2018111049A1 (ko) * 2016-12-15 2018-06-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (de) 2017-02-01 2020-11-25 Beyondspring Pharmaceuticals, Inc. Verfahren zur reduzierung von neutropenie
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
EP3787751A1 (de) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Kombinationstherapie aus einer chimären antigen-rezeptor(car)-t-zelltherapie und einem kinaseinhibitor
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
EP4319751A4 (de) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. Therapeutische zusammensetzungen und verfahren zur behandlung von tumoren
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2025188028A1 (ko) * 2024-03-05 2025-09-12 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL242547A (de) * 1958-08-22
DE2145178C3 (de) * 1970-09-11 1975-12-11 Tokyo Tanabe Co., Ltd., Tokio 2-Phenyl-5-oder -6-benzothiazolylessigsäure-Verblndungen
JPS4932855B1 (de) * 1971-08-03 1974-09-03
DD150059A1 (de) * 1980-04-07 1981-08-12 Horst Hartmann Verfahren zur herstellung von hydroxyarylazolen
JPS62221679A (ja) * 1986-03-19 1987-09-29 Santen Pharmaceut Co Ltd ベンゾチアゾリン誘導体
DE4030511A1 (de) * 1990-09-27 1992-04-02 Basf Ag Hochtemperaturbestaendige, benzthiazolhaltige polyarylether
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
IL135176A0 (en) * 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
US6436939B2 (en) * 2000-03-31 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
JP2002306916A (ja) * 2001-01-26 2002-10-22 Toray Ind Inc エアフィルタユニット

Also Published As

Publication number Publication date
JP2006504672A (ja) 2006-02-09
EP1539723B1 (de) 2006-05-24
MXPA05001585A (es) 2005-04-25
SE0202429D0 (sv) 2002-08-14
IL166412A0 (en) 2006-01-15
BR0313407A (pt) 2005-07-05
US20060106015A1 (en) 2006-05-18
CA2495492A1 (en) 2004-02-26
NO20051263L (no) 2005-05-12
CN1675189A (zh) 2005-09-28
EP1539723A1 (de) 2005-06-15
DE60305514D1 (de) 2006-06-29
ZA200501098B (en) 2006-12-27
AU2003248587A1 (en) 2004-03-03
KR20060002728A (ko) 2006-01-09
WO2004016600A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
ATE284860T1 (de) Neue verwendung von phenylheteroalkylamin- derivaten
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
MY157949A (en) Thioxanthine derivatives as myeloperoxidase inhibitors
SE0301232D0 (sv) Novel use
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
SE0104334D0 (sv) Therapeutic agents
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
GB0112348D0 (en) Compounds
NO20044571L (no) Isokinolinderivater
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
ATE293961T1 (de) Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie
DE60103035D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
SE0201193D0 (sv) Novel use
BR0016329A (pt) Bis-indolilmaleimidas substituìdas para inibição de proliferação de células

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties